This research is Trending!
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Key result
The 2023 update stresses early diagnosis and tailored treatment to improve HF outcomes.
Key Points
Key points are not available for this paper at this time.
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“We know that giving the 4 classes of drugs at the optimal dose can reduce all-cause mortality by more than 50%, however, you know that all around the world and there are no exceptions, less than 5% of the patients have a combination of the 4 classes at the target dose.”
“The effect occurs completely independently of the ejection fraction.”
“There are some important comorbidities like diabetes, iron deficiency, and chronic kidney disease that are strongly related with the pathophysiology of HF; all of them create a special metabolic milieu and together promote the progression of HF; therefore, they are of very high importance.”
Implication
Guideline update may inform current HF care; leaves open questions on implementation and outcome validation.
Abstract
International audience
Discussion
No takes yet. Share an insight, caveat, or question.
Cite This Study
McDonagh et al. (2023) studied this question. The 2023 update emphasizes the importance of early diagnosis and tailored treatment strategies in improving outcomes for patients with heart failure.